MEETING ABSTRACT





Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment

T Byrski^{1*}, J Gronwald¹, T Huzarski¹, E Marczyk², P Blecharz², O Ashuryk¹, C Cybulski¹, D Zuziak³, R Wiśniowski³, D Godlewski⁴, SA Narod⁵, J Lubiński¹

From Annual Conference on Hereditary Cancers 2011 Szczecin, Poland. 17-18 November 2011

Aim of study

The aim of this study was to evaluate the frequency of pathological complete response (pCR) in BRCA1 mutation carriers diagnosed with breast cancer treated with preoperative Cisplatin chemotherapy.

Material and methods

Between December 2006 and August 2011 seventy five women with BRCA1 mutation and diagnosed with breast cancer stage I to III were enrolled. Patients were treated with Cisplatin at dose 75 mg/m2 every three weeks for four cycles. After chemotherapy mastectomy was performed and followed with conventional chemotherapy. Seven patients had prior chemotherapy for a previous cancer diagnosis. Four patients received prior chemotherapy for their current cancer diagnosis and then received therapy according to our protocol.

In the group of 67 patients treated with Cisplatin in first line of treatment - 32 met the standard criteria for neoadjuvant chemotherapy, and in 35 cases - the criteria were not met.

Pathologic complete response was determined by review of surgical specimens. Complete pathologic response was defined as no residual invasive disease in both the breast and axilla. Information was collected on clinical stage, grade, hormone receptor status and HER2 status prior to treatment.

Results

A pathologic complete response (pCR) was observed in 47/75 (62,7%) patients, partial response was observed in 27/75 (36%) patients and stable disease in 1/75 (1,3%) patient. After excluding those patients who were treated

* Correspondence: tomekbyr@poczta.onet.pl

¹Pomeranian Medical University, Clinic of Oncology, Szczecin, Poland Full list of author information is available at the end of the article with chemotherapy in the past - pathological complete response was achieved in 45/67 (67,2%) patients. In the group of 25 patients who met the standard criteria for neoadjuvant chemotherapy and treated with Cisplatinmonotherapy as a first line of treatment pathological complete response was achieved in 56% (14/25) patients. In group of remaining 42 patients who did not meet the criteria for neoadjuvant treatment the pathological complete response was achieved in 78,6% (33/42) patients.

Author details

 ¹Pomeranian Medical University, Clinic of Oncology, Szczecin, Poland.
²Oncology Institute, Kraków, Poland.
³Regional Oncology Center, Bielsko-Biała, Poland.
⁴Center for Epidemiology and Prevention, Poznań, Poland.
⁵Women's College Research Institute, Toronto, Ontario, Canada.

Published: 20 April 2012

doi:10.1186/1897-4287-10-S3-A3 Cite this article as: Byrski *et al.*: Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment. *Hereditary Cancer in Clinical Practice* 2012 **10**(Suppl 3):A3.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit



© 2012 Byrski et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.